María
Díez Campelo
Profesora Asociada CC. Salud
Fermín
Sánchez-Guijo Martín
Catedrático de Universidad
Publicaciones en las que colabora con Fermín Sánchez-Guijo Martín (28)
2024
-
Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells
Cytotherapy, Vol. 26, Núm. 8, pp. 806-812
2023
2022
-
Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells
Therapeutic Advances in Hematology, Vol. 13
-
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
Nature Communications, Vol. 13, Núm. 1
2019
-
Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity
British Journal of Haematology, Vol. 187, Núm. 1, pp. 93-104
-
SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: An alternative approach against acute myeloid leukemia
Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1
-
The Incorporation of Extracellular Vesicles from Mesenchymal Stromal Cells Into CD34+ Cells Increases Their Clonogenic Capacity and Bone Marrow Lodging Ability
Stem Cells, Vol. 37, Núm. 10, pp. 1357-1368
2018
-
Mesenchymal Stromal Cell Irradiation Interferes with the Adipogenic/Osteogenic Differentiation Balance and Improves Their Hematopoietic-Supporting Ability
Biology of Blood and Marrow Transplantation, Vol. 24, Núm. 3, pp. 443-451
2016
2015
-
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
Leukemia Research, Vol. 39, Núm. 3, pp. 296-306
2014
-
Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus
Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690
-
Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome
Leukemia Research, Vol. 38, Núm. 5, pp. 551-556
-
Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585
2013
-
Uptake and delivery of antigens by mesenchymal stromal cells
Cytotherapy, Vol. 15, Núm. 6, pp. 673-678
2012
-
Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation
Transfusion, Vol. 52, Núm. 5, pp. 1086-1091
-
Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients
Haematologica, Vol. 97, Núm. 8, pp. 1218-1224
-
Optimisation of mesenchymal stromal cells karyotyping analysis: Implications for clinical use
Transfusion Medicine, Vol. 22, Núm. 2, pp. 122-127
2010
-
Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant
American Journal of Hematology, Vol. 85, Núm. 4, pp. 290-293
2009
-
Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome
Leukemia, Vol. 23, Núm. 4, pp. 664-672
-
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population
Haematologica, Vol. 94, Núm. 7, pp. 975-983